Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Brown Capital Management International All Company Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Brown Capital's International All Company Fund underperformed in Q1 2025 as growth stocks lagged value, but the manager remains confident in their Exceptional Growth Company strategy. Strong performance from MercadoLibre's e-commerce dominance was offset by regulatory uncertainty at ICON and competitive pressures at Novo Nordisk."
Brown Capital Management's International All Company Fund returned -1.62% in Q1 2025, underperforming the MSCI EAFE Index's 7.01% return as money flows favored value over growth companies. The fund maintains its focus on Exceptional Growth Companies with four key criteria: durability, defensibility, deliverability, and profitability. Key contributors included MercadoLibre, which reported strong 37% revenue growth and benefits from Latin America's low e-commerce penetration, and Carl Zeiss Meditec, which showed signs of recovery in ophthalmic equipment demand. Detractors included ICON, facing industry uncertainty from regulatory changes and funding fluctuations, and Novo Nordisk, pressured by competitive concerns in the GLP-1 obesity drug market despite maintaining a duopoly position. The manager believes international equities may benefit from a potential shift away from decades-long U.S. equity preference, driven by geopolitical uncertainties and policy changes. No portfolio changes were made during the quarter, reflecting the long-term investment approach focused on companies with sustainable competitive advantages.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction is demonstrated through detailed analysis of four investment criteria, specific company examples, and maintaining positions despite underperformance. The manager provides clear rationale for holdings and expresses confidence in long-term thesis despite near-term challenges.
Growth Outlook
The manager expresses cautious optimism about international markets, noting the significant outperformance of MSCI EAFE over S&P 500 and suggesting a potential shift in decades-long investor preference toward international equities. However, this is tempered by acknowledgment of geopolitical uncertainties and policy changes.
Risk Appetite
The portfolio positioning remained unchanged during the quarter with no additions or deletions, indicating a neutral stance. The manager maintains existing positions despite underperformance, showing neither aggressive deployment nor defensive positioning.
Capital Deployment
No capital deployment activity occurred during the quarter with zero additions or deletions to the portfolio. The manager maintained existing positions without scaling up or down, indicating neutral deployment stance.
Forward Guidance
The manager expresses confidence that their Exceptional Growth Companies should perform well as fundamentals are appreciated over the long term. They see potential benefits from shifting flows to international equities, indicating a moderately positive forward bias.
Language Signal
Language contains balanced mix of positive terms like 'long runway for growth,' 'significant opportunity,' and 'reinforces our optimism' alongside cautionary language about 'uncertainty,' 'sluggish results,' and 'monitoring closely.' Net balance tilts slightly positive.
Perceived Risk
Moderate risk perception is evident through discussion of geopolitical uncertainties, regulatory changes affecting healthcare companies, competitive pressures in pharmaceuticals, and industry-wide uncertainties. The manager acknowledges multiple risk factors while maintaining positions.
Opportunity Density
The manager identifies selective opportunities in international markets, particularly highlighting underpenetrated markets like Latin American e-commerce and hearing implants. Specific growth opportunities are cited for individual holdings, suggesting moderate opportunity density.
Time Horizon
Strong emphasis on long-term investment horizon with statements about holding companies 'for years or even decades,' owning some positions for over a decade, and focusing on fundamentals being 'fully appreciated' over time. The patient capital approach is clearly articulated.
